Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.3 million.

  • Ernexa Therapeutics' Net Cash Flow rose 4729.0% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 7202.19%. This contributed to the annual value of -$9.9 million for FY2024, which is 15680.7% down from last year.
  • As of Q3 2025, Ernexa Therapeutics' Net Cash Flow stood at -$1.3 million, which was up 4729.0% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Net Cash Flow peaked at $6.8 million during Q1 2021, and registered a low of -$6.2 million during Q3 2022.
  • Its 5-year average for Net Cash Flow is -$447937.5, with a median of -$1.8 million in 2024.
  • In the last 5 years, Ernexa Therapeutics' Net Cash Flow soared by 53321.3% in 2021 and then tumbled by 19284.73% in 2023.
  • Ernexa Therapeutics' Net Cash Flow (Quarter) stood at $6.8 million in 2021, then plummeted by 66.27% to $2.3 million in 2022, then skyrocketed by 32.23% to $3.0 million in 2023, then crashed by 183.83% to -$2.5 million in 2024, then skyrocketed by 49.74% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, $2.4 million for Q2 2025, and $154000.0 during Q1 2025.